-
Antanan ® in China to treat Huntington's disease and delayed movement disorder
Time of Update: 2021-03-10
Huntington's disease is a rare and deadly neurodegenerative disease that affects about 0.4 out of every 100,000 people in Asia, with an average age of 40. - unconscious, random and sudden, twisting a
-
Boan bio-new crown and antibody completed Phase I clinical all subjects into the group
Time of Update: 2021-03-10
LY-CovMab is a recombinant all-human monoclonal neutralizing antibody that binds to the SARS-CoV-2 surface prick protein culture with high affinity specificity, and effectively blocks the binding of the virus to the host cell surface subject ACE2.
LY-CovMab was developed by Boan Bio's all-human antibody genetically modified mouse phage demonstration technology platform.
-
The Mercadon/Bayer heart failure drug Vericiguat has been approved by the FDA
Time of Update: 2021-03-10
patients with a medium follow-up period of 10.8 months showed that the Vericiguat treatment group reduced the risk of compound endpoint death from heart failure hospitalization and cardiovascular causes (35.5% vs.
-
New crown drug: Redsiway 2020 sales expected to exceed $2.8 billion...
Time of Update: 2021-03-10
2. Lianhua Qing Plague: Annual sales are expected to break 4 billion yuan Lianhua Qing Plague Capsules is a new Chinese medicine developed by Ling Pharmaceuticals during the "SARS" period in 2003, approved in April 2020 for the routine treatment of neo-crown pneumonia.
-
PLoS ONE: Opioid use may be directly related to an increased risk of pancreatic cancer in individuals
Time of Update: 2021-03-10
In fact, opioid abuse and overdose have now progressed into a public health crisis facing humanity, with about 70,000 drug overdose deaths reported in 2017, 68 percent of which were related to opioid
-
RHB-204 is eligible for FDA Rapid Review
Time of Update: 2021-03-10
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases (ATS/IDSA Official Statement: Diagnosis, Treatment and Prevention of Non-TB Mycobacteria Disease) American Journal of Respiratory and Intensive Care Medicine.
(Epidemic and clinical characteristics of mycobacteria tuberculosis: a new public health disease) American Journal of Respiratory and Intensive Care Medicine 2010; 182: 977-82
-
Another drug company, Alzheimer's Disease, failed!
Time of Update: 2021-03-10
Unfortunately, in the focused analysis of completed troriluzole as the primary and critical secondary data for phase 2/3 clinical trials for the treatment of mild and moderate AD symptoms, there was no statistical improvement in the use of trorilule at 48 weeks in patients using the Alzheimer's Assessment Scale Cognitive Subscale 11 (ADAS cog) and the Total Clinical Dementia Assessment Scale Box (CDR-SB) compared to the placebo group.
-
Forty-two commonly used drugs are not prescribed
Time of Update: 2021-03-10
April 24, the State Drug Administration issued the Bulletin on the Conversion of Silver Yellow Pill Prescription Drugs to Over-the-Counter Drugs and the Revision of Over-the-Counter Drug Instructions (No. 55 of 2020).
-
These 20 drugs sell best (with list)
Time of Update: 2021-03-10
1, drug sales amount Top20 announced January 8, Fujian Provincial Health Insurance Bureau issued 8, 9, 10, 11, 4 months of sunshine procurement drug sales amount ranked in the top 20 list. , the list
-
The interim measures for the management of fixed-point medical insurance for retail pharmacies make a "negative list" of violations by legal representatives at the headquarters of the drugstore chain or the simultaneous termination of the health insurance agreement for all stores
Time of Update: 2021-03-10
Retail pharmacies shall, at a minimum, provide a copy of the labor contract of the medical insurance professional (and) management personnel, and include the predictive analysis report of the use of the medical insurance fund after the fixed-point.
-
The multi-sclerosis drug Zeposia was rejected by NICE
Time of Update: 2021-03-10
While pricing negotiations between BMS and the UK government are confidential, according to the consultation document, NICE does not consider the cost-effectiveness of the drug to be within the range of resources acceptable to the NHS compared to other first-line relapsed remission-relieving multiple sclerosis (RRMS) treatments.
-
The FDA accepts the nasal drug methyl sulfonate dehydroquinolamine (DHE) INP104
Time of Update: 2021-03-10
the drug was developed using Impel's proprietary Precision Olfactory Delivery (POD) technology and delivered directly to the blood vessel-rich upper nasal cavity, potentially providing convenience and clinical benefits for patients with acute migraines.
-
Centail Pharmaceuticals: Misoprostol tablets are evaluated by consistency
Time of Update: 2021-03-10
because of its uterine contractions, it has been widely used in pregnancy and pregnant women's various adaptive disorders, such as drug abortion, cervical maturation, pre-surgery softening of the cervix and so on.
-
2021 All pharmaceutical companies have to sign this Promise.
Time of Update: 2021-03-10
On the 25th of last month, the State Health Insurance Administration again issued the Notice on Speeding Up the Implementation of the Medical Price and Credit Evaluation System, which requires that the signing of commitments be a top priority at this stage, and that the proportion of written commitments submitted by bidding enterprises should reach more than 80% by the end of February 2021 and more than 95% by the end of March 2021.
-
"Not old medicine" was checked
Time of Update: 2021-03-10
Fengyuan Pharmaceutical Co., Ltd. is mainly involved in 28.4% of the subsidiary Jiangsu Integrity Pharmaceutical Co., Ltd. to participate in NMN products related technology research and development, but there is currently no sales of the product.
-
The European Union approved AZ/13 Enhertu for the treatment of advanced breast cancer
Time of Update: 2021-03-10
AZ/First Third Total Enhertu Third-Line Treatment of Advanced Breast Cancer The European Commission's approval is based on positive results from phase II clinical trials of single-armESTINY-Breast01, and approves applications for the drug in accordance with the recommendations of the European Medicines Agency (EMA) Commission on Human Use (CMPH) in December 2020, in accordance with the accelerated evaluation process.
-
Positive results were obtained in the phase III clinical trial of positive day clear PD-1 in the first-line advanced liver cancer in Androgenini
Time of Update: 2021-03-10
results of this clinical study on hepatocellular carcinoma show that, as of November 2020, the objective remission rate (ORR) of the first-line treatment HCC for the combined low dose of amphrotinium (8 mg, two consecutive weeks, one week of suspension) was 31 .0%, with a disease control rate (DCR) of 82.8%, a medium progress-free lifetime (PFS) of 8.8 months, a six-month PFS rate of 63.2%, and a six-month OS rate of 93.2%.
-
Orphan Medicine Weekly | Amjin, Novarma, Asathe Pharmaceuticals and other companies 9 therapies shortlisted
Time of Update: 2021-03-10
Drugs: ATI-450 Research and Development Enterprise: Aclaris Therapeutics Treatment of Diseases: Cryopyrin-associated periodic syndrome (Cryopyrin-associated periodic syndrome, CAPS) Introduction: ATI-450 is an oral small molecule inhibitor targeting the p38 alpha fissure active protein kinase active protein kinase 2 (MK2) inflammatory signaling path.
-
Another pharmaceutical company employee was diagnosed!
Time of Update: 2021-03-10
One of the workers in Shijiazhuang's new confirmed case of neo-crown pneumonia is a pharmaceutical factory worker. confirmed cases 63: male, 59 years old, Yancheng Zeng village town niujiazhuang vill
-
Global cumulative diagnosis of nearly 100 million vaccine crazy antibody struggle can save the outbreak in the water and fire?
Time of Update: 2021-03-10
same day, in China, a team of chen Wei academicians in military medical research from the Chinese Academy of Military Sciences and a recombinant new crown vaccine developed by Concino Bio announced that they had been approved for clinical use and began recruiting volunteers.
